Alnylam Pharma ALNY

HealthcareMarket cap $34B3 connections

Alnylam invented RNA interference (RNAi) therapy - using small molecules to silence disease-causing genes. Its Onpattro (patisiran) was the first approved RNAi drug. Its pipeline targets rare genetic diseases including ATTR amyloidosis (heart disease) and hypertension. RNAi is a transformative platform applicable to hundreds of diseases.

Open Alnylam Pharma's Company Hub Simulate a merger Supply chain See it on the map

Partners 3

Strategic partnerships, joint products and alliances

Gilead SciencesHealthcare · $187BCompeting RNA-based rare disease platforms
Arrowhead PharmaHealthcare · $9BCompeting RNAi therapeutic companies
Ionis PharmaHealthcare · $7BCompeting RNA silencing therapeutic companies

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Alnylam Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=ALNY" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Alnylam Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.